Table 4 Clinical performance of the SHOX2 DNA methylation biomarker with regards to cytology (only from 523 valid samples passing the quality criterion).
From: SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates
Cytology Result | Cases Total | Controls Total | Test Positive Cases (Sensitivity [%]) | Test Negative Controls (Specificity [%]) |
|---|---|---|---|---|
All | 281 | 242 | 190 (68%) | 230 (95%) |
Unknown | 187 | 180 | 128 (68%) | 171 (95%) |
Negative | 73 | 62 | 45 (62%) | 59 (95%) |
Suspicious | 15 | 0 | 12 (80%) | - |
Positive | 6 | 0 | 5 (83%) | - |